Selective IgA Deficiency

Definition and diagnostic criteria

Definition: Serum IgA < 7 mg/dL with normal IgG and IgM in a patient older than 4 years after excluding secondary causes of hypogammaglobulinemia.

Confirmatory steps: Repeat measurement to confirm persistence; review medications, protein‑losing states, renal loss, and other secondary causes before labeling as primary selective IgA deficiency.

Epidemiology

Frequency: Most common primary antibody deficiency; prevalence varies by population and study design but is commonly reported in the range of ~1:200–1:900 (often cited ~1:300–1:700 in Caucasian cohorts).

Clinical penetrance: Most patients are asymptomatic, but a clinically important minority have recurrent infections, autoimmunity, or evolving antibody deficiencies over time.

Clinical features relevant to pediatric gastroenterology

• General infection risk: Increased risk of recurrent sinopulmonary infections; risk higher when coexisting IgG2 deficiency or poor specific antibody responses is present.
• GI infections: Predisposition to chronic or recurrent giardiasis and other enteric infections.
• Celiac disease: Increased prevalence compared with the general population; clinical presentation and histology mirror IgA‑sufficient patients aside from reduced/absent IgA plasma cells in lamina propria.
• Inflammatory and lymphoid changes: Association with nodular lymphoid hyperplasia and a higher prevalence of inflammatory bowel disease and autoimmune GI conditions in some cohorts.
• Transfusion risk: Rare patients develop anti‑IgA alloantibodies and may experience anaphylactic transfusion reactions to blood products containing IgA.

Testing approach practical points for gastroenterology

Concurrent testing for celiac disease

Always request a total serum IgA level alongside IgA‑based celiac serology so negative IgA tests can be interpreted correctly.

If total IgA is low or undetectable

Use IgG‑based celiac tests (anti‑tTG IgG, deamidated gliadin peptide IgG) rather than IgA‑based anti‑tTG or anti‑endomysial assays.

Broader immunologic evaluation when indicated

Check IgG, IgM, vaccine responses (eg, pneumococcal titers), and consider IgG subclass testing for recurrent infections or unusual clinical courses.

Endoscopy and biopsy interpretation

Mucosal findings of celiac disease or other enteropathies are interpreted the same as in IgA‑sufficient patients; immunostaining may show absent or reduced IgA+ plasma cells.

Management and referral

• Asymptomatic patients: No routine therapy; provide education and periodic clinical follow‑up.
• Infections: Treat acute infections per standard guidelines; evaluate and treat chronic giardiasis promptly; consider prophylactic strategies or immunology input for recurrent severe infections.
• Celiac disease: Initiate gluten‑free diet when diagnosis is confirmed clinically and/or histologically; if symptoms or mucosal lesions do not respond, pursue immunology evaluation for possible evolving antibody deficiency such as CVID.
• Immunology referral: Indications include recurrent or severe infections, poor vaccine responses, evolving hypogammaglobulinemia, unexplained systemic autoimmunity, or complications requiring immunoglobulin replacement consideration.
• Blood product precautions: For patients with prior transfusion reactions or known anti‑IgA antibodies, coordinate with transfusion medicine for IgA‑reduced products and pretransfusion planning.

Follow-up and prognosis

Many patients remain clinically stable and asymptomatic; a subset will develop autoimmune conditions, chronic GI disease, or progress to broader antibody deficiencies such as CVID over time.

Recommended follow‑up includes periodic clinical reassessment, repeat immunologic testing if new infections or autoimmunity appear, and monitoring vaccine responses as clinically indicated.

Clinical pearls